Bladder Cancer Data Improves Across Key Endpoints, BLA Filing Planned
ENGN sits 30% above its 52-week low of $1.4 on elevated volume (3.4× avg).
Summary
Updated Phase 2 LEGEND Cohort 1 data for detalimogene in high-risk, BCG-unresponsive non-muscle invasive bladder cancer improved on every key measure. Complete response rose to 56% from 54%, the preliminary 12-month duration of response estimate jumped to 43% from 25%, median DoR extended to 10.1 months from 8.6, and the 12-month CR rate doubled to 24% from 13%. Serious treatment-related adverse events stayed at just 2% of patients. Management now says the 125-patient dataset will form the basis of a BLA submission to the FDA, which follows the September 8 disclosure that a detalimogene BLA was planned. The company also named Erik T. Goluboff as chief medical officer and Jason Duncan as chief legal and administrative officer, effective November 9, 2026. Shares closed 7% higher Wednesday and added over 1% after hours, though the stock is still down 80% year to date — the durability gains are what matter here, since duration of response is the endpoint that decides whether this asset is approvable.
At the time of this announcement, ENGN was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.6M. The 52-week trading range was $1.40 to $12.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.